Atai Life Sciences Dividends and Buybacks
Dividend criteria checks 0/6
Atai Life Sciences does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.2%
Buyback Yield
| Total Shareholder Yield | -0.2% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Psychedelic Stock Deep Dive: Atai Life Sciences
Sep 03Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15
ATAI: Enormous Potential Upside But No Clarity Yet
May 27Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ATAI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATAI's dividend payments have been increasing.
Dividend Yield vs Market
| Atai Life Sciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ATAI) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Pharmaceuticals) | 2.6% |
| Analyst forecast (ATAI) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ATAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ATAI's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ATAI has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 22:27 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atai Life Sciences N.V. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |